FDA Streamlines Approval Path for Neurizon's ALS Treatment Candidate

The FDA has indicated to Neurizon Therapeutics that a single positive pivotal study could suffice for traditional approval of its ALS drug candidate, NUZ-001, potentially accelerating its market entry. Neurizon has already completed enrollment for its Phase 2/3 HEALEY ALS Platform Trial ahead of schedule, with topline results anticipated in mid-2027. The company has also been invited to resubmit its Fast Track Designation request.